A neutral CB1 receptor antagonist reduces weight gain in rat. (Q46932962)

26 December 2017

title

A neutral CB1 receptor antagonist reduces weight gain in rat. (English)

1 reference

26 December 2017

1 reference

6

1 reference

26 December 2017

Keith A. Sharkey

8

1 reference

26 December 2017

Alexandros Makriyannis

7

object named as

Alexandros Makriyannis

1 reference

26 December 2017

2

V Kiran Vemuri

1 reference

26 December 2017

Jodianne T Wood

4

object named as

Jodianne T Wood

1 reference

26 December 2017

author name string

Adam P Chambers

1

1 reference

26 December 2017

Yan Peng

3

1 reference

26 December 2017

Teresa Olszewska

5

1 reference

26 December 2017

publication date

24 October 2007

1 reference

26 December 2017

American Journal of Physiology - Regulatory, Integrative and Comparative Physiology

published in

1 reference

26 December 2017

volume

293

1 reference

26 December 2017

issue

6

1 reference

26 December 2017

page(s)

R2185-93

1 reference

26 December 2017

The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells

cites work

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00663.2007

Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00663.2007

Role of the preoptic-anterior hypothalamus in thermoregulation and fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00663.2007

Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00663.2007

AM 251 produces sustained reductions in food intake and body weight that are resistant to tolerance and conditioned taste aversion

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00663.2007

Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00663.2007

Appetite suppression and weight loss after the cannabinoid antagonist SR 141716.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00663.2007

The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00663.2007

Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00663.2007

Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00663.2007

The emerging role of cannabinoid neuromodulators in symptom management

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00663.2007

Behavioral effects of cannabinoids show differential sensitivity to cannabinoid receptor blockade and tolerance development

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00663.2007

Behavioral mechanisms underlying inhibition of food-maintained responding by the cannabinoid receptor antagonist/inverse agonist SR141716A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00663.2007

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00663.2007

Effects of rimonabant (SR141716) on fasting-induced hypothalamic-pituitary-adrenal axis and neuronal activation in lean and obese Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00663.2007

Review article: endocannabinoids and their receptors in the enteric nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00663.2007

Changes in body temperature and oxygen consumption rate of conscious mice produced by intrahypothalamic and intracerebroventricular injections of delta 9-tetrahydrocannabinol

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00663.2007

Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00663.2007

Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00663.2007

Central neurocircuitry associated with emesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00663.2007

Discovery of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1h-1,2,4-triazole, a novel in vivo cannabinoid antagonist containing a 1,2,4-triazole motif

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00663.2007

The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00663.2007

Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00663.2007

Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00663.2007

Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00663.2007

Albumin enhances the diffusion of lipophilic drugs into the membrane bilayer

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00663.2007

Endogenous cannabinoids in the brain and peripheral tissues: regulation of their levels and control of food intake.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00663.2007

Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00663.2007

Suppression of food intake and food-reinforced behavior produced by the novel CB1 receptor antagonist/inverse agonist AM 1387.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00663.2007

The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and food-reinforced behavior in a variety of tasks in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00663.2007

The cannabinoid CB1 antagonist AM 251 produces food avoidance and behaviors associated with nausea but does not impair feeding efficiency in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00663.2007

Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00663.2007

Some implications of receptor theory for in vivo assessment of agonists, antagonists and inverse agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00663.2007

Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole--LH 21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00663.2007

Inverse agonism and neutral antagonism at cannabinoid CB1 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00663.2007

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00663.2007

Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00663.2007

CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00663.2007

Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00663.2007

Rapid glucocorticoid actions in the hypothalamus as a mechanism of homeostatic integration

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00663.2007

The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00663.2007

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00663.2007

Identification and functional characterization of brainstem cannabinoid CB2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00663.2007

Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00663.2007

Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00663.2007

10.1152/AJPREGU.00663.2007

21 January 2018

Identifiers

DOI

1 reference

26 December 2017

PubMed ID

17959701

1 reference

26 December 2017